Form 4: Castle Biosciences CFO Frank Stokes Sells Shares Under 10b5-1 Plan

Frank Stokes, CFO of Castle Biosciences, sold 8,046 shares of common stock at an average price of $26.70 on February 20, 2025, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On February 20, 2025, Frank Stokes, the Chief Financial Officer of Castle Biosciences, sold 8,046 shares of the company's common stock.
• The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2024.
• The shares were sold at prices ranging from $26.47 to $27.10, with a weighted-average sale price of $26.70.
• Following the transaction, Stokes directly owns 35,319 shares of Castle Biosciences common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transaction was pre-planned under a 10b5-1 plan and doesn't necessarily reflect a negative outlook on the company.

Industry Context

Sales by insiders are a common occurrence and are often pre-planned through Rule 10b5-1 plans to avoid accusations of trading on non-public information. The market typically views these sales in the context of the individual's overall holdings and the reasons behind the sale (e.g., diversification, personal financial needs).

Stakeholder Impact

• The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates

Keywords

Form 4, Castle Biosciences, CSTL, Frank Stokes, Chief Financial Officer, Stock Sale, Rule 10b5-1 plan, Insider Trading